MedPharm’s Center for Skin Biology (CSB) provides scientifically rigorous, end-to-end support for substantiating cosmetic and personal care claims. With over 25 years of skin biology expertise, proprietary human skin models, and integrated preclinical and clinical capabilities, CSB generates reliable, performance-based data to support product claims and differentiate brands in a competitive market. View Publication

This one-page overview highlights MedPharm’s end-to-end capabilities in topical, transdermal, and transepithelial drug development. From early-stage formulation and in vitro testing through clinical trial material supply and commercial manufacturing, MedPharm supports programs at every stage to accelerate development and reduce risk. Download Overview

The aim of process development is to establish optimal process parameters and conditions for future large-scale batches or commercialization, ensuring that the product can be successfully manufactured in compliance with required quality and regulatory standards. This ultimately means that an in-depth understanding of the formulation is key.

Unlike solid dosage drug products and sterile injectables, topical and transdermal formulations often contain a higher number of excipients, making them more complex to develop and scale. Given that the processes that can be used for manufacturing a drug product are largely impacted by the specific components of that product’s composition, a strong comprehension of the formulation is key.